Lombard Medical Technologies (LON:LMT) said today that it’s tabling a planned initial public offering on the NASDAQ exchange due to adverse conditions in the U.S. stock market.
Funding Roundup
DOD hands out $99.6 million in contracts to Hologic, GE, PositiveID | Medtech funding stories for the week of Apr. 7, 2014
Tendyne Holdings secures $25M for transcatheter mitral valves
Medtech startup Tendyne Holdings landed $25 million in Series C funding, planning on using the new cash for further research & development of its transcatheter mitral valve technology.
The 4-year-old company’s device provides minimally invasive treatment of mitral regurgitation. Tendyne is working on engineering an implantation system that would allow physicians to re-position or retrieve the valve even after full deployment.
InfoBionic lands $17M for remote patient monitoring
Digital health startup InfoBionic secured $17 million in Series B financing in support of its remote patient monitoring platform.
InfoBionic plans to use the funds to commercialize its MoMe monitoring platform, which utilizes cloud, smartphone and web services that connect with sensors worn by patients. The company’s current focus is on cardiac arrhythmias.
Sequent Medical raises $20M Series D for brain aneurysm device
Sequent Medical said it raised a Series D round worth $20 million from its slate of previous investors, led again by Delphi Ventures.
Domain Associates, US Venture Partners and Versant Ventures also participated, Sequent said.
Deerfield raises $1.6B healthcare fund
Deerfield Management Co. said it raised a fund aimed at healthcare investments that’s worth $1.6 billion.
Deerfield Private Design Fund III is "designed to provide flexible private financing to healthcare companies," according to a press release.
Vital Therapies lowers the bar with 2nd IPO try
Bio-artificial liver maker Vital Therapies set the range for its initial public offering at $13 to $15 per share, below the $16 to $18 range it set last year before scuttling its 1st try at a U.S. IPO.
In March Vital Therapies filed updated registration statements signaling its intent to launch the IPO, wiping clean the pricing set in November 2013. Another filing today set the new price range for the 4.5-million-share offering at $58.5 million to $67.5 million.
Hologic, GE, PositiveID land near $100M in Defense contracts
The U.S. Dept. of Defense handed out $99.6 million in contracts to a trio of device makers, providing for radiology systems, patient monitoring and airborne bio-threat detection for a variety of military and civilian agencies.
Cancer: RefleXion Medical raises $11.6M to ‘make radiotherapy personal’
California-based medtech group RefleXion Medical touted an $11.6 million Series A fundraising round, hoping to use the new funds to expand research & development efforts for its guided radiation therapy technology.
TriVascular Technologies sets price range for $98M IPO
TriVascular Technologies said it could raise as much as $98 million from its planned initial public offering after setting the per-share price range at $13-$15.
That would set the top end of the 6.5-million-share offering at $97.5 million, or $84.5 million at the low end.
Foresite Capital secures $300M for late-stage healthcare investment fund
Healthcare investment firm Foresite Capital has a new $300 million pool to spend on late-stage healthcare firms, and the company is looking for "transformative" innovations.
Coming off of a $100 million fundraiser just earlier this year, Foresite closed its latest round with an over-subscription of capital commitments for healthcare investment.